Comparative Pharmacology
Head-to-head clinical analysis: BONSITY versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONSITY versus FOSAMAX.
BONSITY vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective estrogen receptor modulator (SERM); binds to estrogen receptors, exerting agonistic effects on bone and lipid metabolism and antagonistic effects on breast and uterine tissue.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
10 mg orally once daily, taken with or without food.
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours; this supports once-daily dosing. Half-life may be prolonged in renal impairment.
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose; biliary/fecal elimination comprises 20-25% as metabolites and unchanged drug.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate